382 related articles for article (PubMed ID: 26349824)
1. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline.
Honeyman L; Ismail M; Nelson ML; Bhatia B; Bowser TE; Chen J; Mechiche R; Ohemeng K; Verma AK; Cannon EP; Macone A; Tanaka SK; Levy S
Antimicrob Agents Chemother; 2015 Nov; 59(11):7044-53. PubMed ID: 26349824
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.
Macone AB; Caruso BK; Leahy RG; Donatelli J; Weir S; Draper MP; Tanaka SK; Levy SB
Antimicrob Agents Chemother; 2014; 58(2):1127-35. PubMed ID: 24295985
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
Petersen PJ; Jacobus NV; Weiss WJ; Sum PE; Testa RT
Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
Huband MD; Pfaller MA; Shortridge D; Flamm RK
J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
[TBL] [Abstract][Full Text] [Related]
5. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections.
Villano S; Steenbergen J; Loh E
Future Microbiol; 2016 Oct; 11():1421-1434. PubMed ID: 27539442
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.
Testa RT; Petersen PJ; Jacobus NV; Sum PE; Lee VJ; Tally FP
Antimicrob Agents Chemother; 1993 Nov; 37(11):2270-7. PubMed ID: 8285606
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of eravacycline and mechanisms of resistance in enterococci.
Boukthir S; Dejoies L; Zouari A; Collet A; Potrel S; Auger G; Cattoir V
Int J Antimicrob Agents; 2020 Dec; 56(6):106215. PubMed ID: 33122095
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Garrison MW; Nuemiller JJ
Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
[TBL] [Abstract][Full Text] [Related]
9. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
11. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in tetracycline antibiotics.
Sum PE; Sum FW; Projan SJ
Curr Pharm Des; 1998 Apr; 4(2):119-32. PubMed ID: 10197036
[TBL] [Abstract][Full Text] [Related]
13. Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.
Jones RN; Wilson ML; Weinstein MP; Stilwell MG; Mendes RE
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):402-5. PubMed ID: 23514756
[TBL] [Abstract][Full Text] [Related]
14. Microbiology and Preclinical Review of Omadacycline.
Karlowsky JA; Steenbergen J; Zhanel GG
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S6-S15. PubMed ID: 31367743
[TBL] [Abstract][Full Text] [Related]
15. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
Li JT; Li Y; Wang J;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911
[TBL] [Abstract][Full Text] [Related]
16. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
17. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.
Borbone S; Lupo A; Mezzatesta ML; Campanile F; Santagati M; Stefani S
Int J Antimicrob Agents; 2008 Mar; 31(3):209-15. PubMed ID: 17646087
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]